Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression

Haematologica

Volumn 93, Issue 4, 2008, Pages 560-565

  Mateos, María Victoria ^a,u   Hernández, José M ^b,u   Hernández, Miguel T ^c,u   Gutiérrez, Norma C ^a,u   Palomera, Luis ^d,u   Fuertes, Marta ^e,u   Garcia Sanchez, Pedro ^f,u   Lahuerta, Juán J ^g,u   De La Rubia, Javier ^h,u   Terol, María José ^i,u   Sureda, Ana ^j,u   Bargay, Joan ^k,u   Ribas, Paz ^l,u   Alegre, Adrian ^m,u   De Arriba, Felipe ^n,u   Oriol, Albert ^o,u   Carrera, Dolores ^p,u   García Laraña, José ^q,u   García Sanz, Ramón ^a,u   Bladé, Joan ^r,u   Prósper, Felipe ^s,u   Mateo, Gemma ^a,u   Esseltine, Dixie Lee ^j,u   Van De Velde, Helgi ^t,u   San Miguel, Jesús F ^a,u,v,w   more..

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL GENERAL DE SEGOVIA   (Spain)

^c HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^e Hospital Virgen Blanca   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^k Hospital Sont Llatzer de Palma de Mallorca   (Spain)

^l Hospital Dr Pesset de Alicante   (Spain)

^m HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁿ HOSPITAL MORALES MESEGUER   (Spain)

^o HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^p HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^q HOSPITAL RAMÓN Y CAJAL   (Spain)

^r INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^s UNIVERSITY CLINIC OF NAVARRA   (Spain)

^t JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^u PETHEMA GEM Grupo Español de MM   (Spain)

^v CSIC   (Spain)

^w NONE   (Spain)

more..

Author keywords

Bortezomib; Clinical trial; Elderly; First line; Melphalan; Multiple myeloma; Prednisone

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BORTEZOMIB; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE;

AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INFECTION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MELPHALAN; MULTIPLE MYELOMA; PREDNISONE; PROGNOSIS; PYRAZINES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 42149176608     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12106     Document Type: Article

References (26)

1. Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991;9:444-8.
2. Facon T, Mary JY, Pegourie B, Attal M, Renaud M, Sadoun A, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292-8.
3. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832-42.
4. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 2006;108:2165-72.
5. Facon T, Mary J, Harousseau J, Huguet F, Berthou C, Grosbois B, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol 2006;24:1s.
6. Hulin C, Virion J, Leleu X, Rodon P, Pegourie B, Benboubker L, et al. Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial. J Clin Oncol 2007;25:441s.
7. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31.
8. Palumbo A, Falco P, Falcone A, Corradini P, Di Raimondo F, Giuliani N, et al. Oral Revlimid® plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter phase I/II study. Blood 2006;108:240a.
9. Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 2005;104:1428-33.
10. Palumbo A, Falco P, Corradini P, Crippa C, Di Raimondo F, Falcone A, et al. Oral melphalan, prednisone and lenalidomide for elderly newly diagnosed myeloma patients. Haematologica 2007;92[Suppl 1]:148. Abs.0402.
11. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
12. Hernandez JM, Garcia-Sanz R, Golvano E, Blade J, Fernandez-Calvo J, Trujillo J, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004;127:159-64.
13. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
14. Gutierrez NC, Castellanos MV, Martin ML, Mateos MV, Hernandez JM, Fernandez M, et al. Prognostic and biological implications of genetic abnormalities in multiple myelo ma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007;21:143-50.
15. Bladé J, Munoz M, Fontanillas M, San Miguel J, Alcala A, Maldonado J, et al. Treatment of multiple myeloma in elderly people: long-term results in 178 patients. Age Ageing 1996;25:357-61.
16. Anagnostopoulos A, Gika D, Symeonidis A, Zervas K, Pouli A, Repoussis P, et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol 2005;75:370-5.
17. Facon T, vet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-71.
18. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000;95:1925-30.
19. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005;23:6339-44.
20. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21:529-34.
21. Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151-7.
22. Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21:164-8.
23. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol 2001;68:269-75.
24. García-Sanz R, González-Fraile MI, Mateo G, Hernández JM, López-Berges MC, de las Heras N, et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer 2004;112:884-9.
25. San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F, et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995;85:448-55.
26. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology™ Multiple Myeloma (V.1.2008). 2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pd. Accessed: 5 October 2007.